Wed, Apr 26, 2023 page10

• World Business Quick Take

  • Agencies
  • • 
    • 
    • 

  BANKING

  Central banks cut Fed swaps

  From Monday next week, the world’s top central banks will reduce the frequency of their US dollar operations with the US Federal Reserve after volatility in financial markets receded, the banks said in a joint statement yesterday. The European Central Bank (ECB) the Bank of Japan, the Bank of England and the Swiss National Bank have been conducting daily US dollar swaps with the Fed for the past month, but will revert to weekly tenders, given improvements in US dollar funding conditions, they said. The daily tenders were made available after the failure of Silicon Valley Bank and the sale of Credit Suisse sent jitters across financial markets, raising the risk of liquidity shortages in case confidence falls further. However, the facility was barely used and the takeup was at or near zero on most days since the facility was announced on March 19. “These central banks stand ready to re-adjust the provision of US dollar liquidity as warranted by market conditions,” the ECB said in a statement.

  FOOD

  Price hikes lift Nestle sales

  Nestle SA’s sales growth unexpectedly accelerated, bolstered by Purina and Friskies petfood and as the maker of Nescafe coffee raised prices further. Sales rose 9.3 percent on an organic basis in the first quarter, Nestle said yesterday. Demand was more resilient than expected, as the maker of KitKat bars kept boosting prices near the highest rate in decades. Nestle said pet owners helped drive an increase of 16 percent in petcare revenue. The next biggest gains were in confectionery and coffee, it said. Despite very strong headline numbers, individual units betrayed some weaknesses: Sales declined at Nespresso and Nestle’s vitamins, supplements and minerals business. Capacity constrains also weighed on the water brand Perrier, the company said.

  PHARMACEUTICALS

  Novartis raises profit outlook

  Parmaceutical giant Novartis AG yesterday said it was increasing its full-year sales and profits outlook after strong earnings in the first quarter on the back of a handful of new drugs. The Swiss drugmaker said that its medicines for heart disease, cancer and multiple sclerosis had buoyed earnings in the quarter. The group reported a 3 percent increase in net profit in the first quarter to nearly US$2.3 billion, while sales also rose 3 percent compared with the previous three months to almost US$13 billion. Novartis said that its operating profit would likely increase in the high single-digits this year on the back of strong momentum at the start of the year, while group sales are expected to grow in mid-single digits.

  INDUSTRIALS

  ABB raises sales forecast

  ABB Ltd yesterday raised its guidance for the year after a surge of new orders added to its backlog and higher prices drove better-than-expected results. The Swiss industrial manufacturer now expects comparable revenue to increase more than 10 percent this year, after estimating about 5 percent in February, it said in a statement. New customer orders reached US$9.5 billion in the first quarter, an increase of 1 percent from a year earlier and exceeding an average analyst estimate of US$8.3 billion, it said. ABB added that it plans to delist its American depositary receipts from the New York Stock Exchange, saying it is no longer necessary that investors can trade digitally on multiple platforms. The delisting is expected to take effect on or around May 23.
• Most Popular

  • 1

    Taiwan win Premier12 title

  • 2

    Taiwan advance to Premier12 gold match

  • 3

    TSMC starts equipment installation for 2nm fab

  • 4

    TSMC to push US to No. 2 in IC production in 2027

  • 5

    Baseball team parade draws thousands